Marketing Programs Manager, Core Labs

Job Location
San Diego, CA 92122


Job Description

All About You

The Marketing Program Manager, Core Labs is responsible for driving business through this channel in the Americas by building and executing targeted programs. This individual will interact with sales and marketing to increase overall revenue through strategic focus and support of customers providing genomic services. The ideal candidate will have a marketing and/or sales background with hands-on laboratory experience.


  • Lead the execution of an Americas’ focused core lab program

  • Develop co-marketing opportunities to drive new customer acquisition

  • Advocate for the needs of these customers by formalizing VOC collection and sharing with appropriate internal groups

  • Work with global marketing to develop core lab focused sales tools and collateral

  • Accelerate product adoption and pull-through in core labs

  • Organize core lab director activities to encourage networking and sharing of best practice

  • Prioritize and capture opportunities at the regional, segment, application and account levels

  • Yearly and quarterly program planning and KPI reporting

  • 30-40% travel required


Preferred Educational Background:

  • Bachelor’s degree required; MBA a plus

Preferred Experiential Background:

  • Minimum 3 years sales or marketing experience in Life Science

  • Minimum 2 year hands-on lab experience, either in school or professionally

  • Must have strong analytical skills and ability to tie detailed analysis to larger strategy

  • Must have strong leadership and presentation skills, orally and written

  • Must have demonstrated effective collaboration in a matrix or highly cross-functional business setting

  • Experiencing working in a core lab facility is a huge plus

EOE / Minorities / Females / Veterans / Disabled

About Our Organization

All About Us

Headquartered in San Diego, California, Illumina (NASDAQ: ILMN), is a leading developer, manufacturer, and marketer of next generation life science tools and integrated systems for large-scale analysis of genetic variation and biological function. These systems are enabling studies that were not even imaginable just a few years ago, and moving us closer to the realization of personalized medicine. With the innovative advances in our sequencing technologies, we are rapidly impacting the clinical market in areas such as reproductive health and oncology. The expanding Illumina oncology portfolio of next- generation sequencing NGS and microarray technologies is revolutionizing cancer genomics research. Our customers include a broad range of academic, government, pharmaceutical, biotechnology, and other leading institutions around the globe.

lllumina has experienced phenomenal growth from $10 million in revenues in 2002 to over $1.4 billion in 2013. Forbes named Illumina #1 on the 2009 list of 25 Fastest-Growing Technology Companies in the United States, the second time over a three year period that Forbes ranked Illumina #1 on its list of rapidly growing technology companies. Illumina was also named #1 smartest company in the world as part of MIT’s 2014 Technology Review. As of August 2014, the company had a $24 billion market capitalization.

An analysis appearing in PeerJ finds that social media mentions of a paper may lead to increased citations.

NIH's Michael Lauer looks at the number of grants, their amount, and funding success rates at the agency for last year.

At Nature, Johns Hopkins' Gundula Bosch describes her graduate program that aims to get doctoral students thinking about the big picture.

Patricia Fara writes about childcare funding, and women in science and science history at NPR.